The Rosen Law Firm, P.A. says it is reviewing potential claims tied to The Cooper Companies, Inc.’s investor disclosures, citing an alleged information problem and a 14.6% share decline on Sept. 10.
The firm alleges Cooper may have given investors materially misleading business information and says it is preparing a class action to seek recovery of shareholder losses. Its notice names no court or filing date.
Rosen points to the share decline the day after Cooper released fiscal third-quarter 2026 results and announced the outcome of a review of CooperSurgical. Cooper is a medical-device company with CooperVision, its contact-lens business, and CooperSurgical, which focuses on fertility and women’s health.
For the quarter ended July 31, Cooper reported revenue of $1.066 billion, up 1% from a year earlier. Non-GAAP diluted earnings per share were $1.15, a 4% increase. GAAP diluted earnings per share were $2.24, primarily reflecting a $307.2 million discrete tax benefit.
Cooper forecast fiscal fourth-quarter 2026 revenue of $1.057 billion to $1.080 billion and non-GAAP diluted earnings per share of $1.05 to $1.09. The company said reductions in U.S. channel inventory at CooperVision weighed on third-quarter results and would continue to affect the fourth quarter.
After reviewing offers, Cooper’s board chose to retain CooperSurgical and raised the share-repurchase authorization from $2 billion to $3 billion. The company said temporary valuation factors contributed to a gap between the offers and the board’s assessment of shareholder interests. Those factors included a competitive entrant in the non-hormonal IUD market and a fertility litigation settlement.
Cooper said it expects to provide further updates on operational initiatives, capital allocation priorities and growth investments over the coming quarters.
